A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia

Dementia and Geriatric Cognitive Disorders

Volumn 24, Issue 1, 2007, Pages 36-41

  De Vasconcelos Cunha, Ulisses Gabriel ^a,b   Lopes Rocha, Fábio ^a   Ávila De Melo, Rodrigo ^a   Alves Valle, Estevão ^a   De Souza Neto, José Júlio ^a   Mendes Brega, Rodrigo ^a   Magalhães Scoralick, Francisca ^a   Araújo Silva, Silvana ^a   Martins De Oliveira, Flaviana ^a   Da Costa Júnior, Antônio Luciano ^a   Xavier Faria Alves, Viviane ^a   Sakurai, Emília ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NONE   (Brazil)

Author keywords

Dementia, depression; Dementia, elderly; Venlafaxine

Indexed keywords

HALOPERIDOL; HYPNOTIC AGENT; NEUROLEPTIC AGENT; PLACEBO; VENLAFAXINE;

AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; CYCLOHEXANOLS; DEMENTIA; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PSYCHOMOTOR AGITATION; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 34250797929     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102570     Document Type: Article

References (36)

1. Bouchard RW, Rossor MN: Typical clinical features;in Gauthier S (ed): Clinical Diagnosis and Management of Alzheimer's Disease. London, Dunitz, 2001, pp 57-71.
2. Baldwin RC, Anderson D, Black S, et al: Guideline for the management of late-life depression in primary care. Int J Geriatr Psychiatry 2003;18:829-838.
3. Beekman AT, Copeland JR, Prince MJ: Review of community prevalence of depression in later life. Br J Psychiatry 1999;174:307-311.
4. Lebowitz BD, Pearson JI, Schneider LS, et al: Diagnosis and treatment of depression in later life. JAMA 1997;278:1186-1190.
5. Ballard C, Bannister C, Solis M, Oyebode F, Wilcock G: The prevalence, association and symptoms of depression amongst dementia sufferers. J Affect Disord 1996;36:136-144.
6. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzheimer disease. III. Disorders of mood. Br J Psychiatry 1990;157:81-86.
7. Gonzales-Salvador T, Lyketsos CG, Baker AS, Roques C, Hovanec L, Steele CD, Brandt J: Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry 2000;15:181-189.
8. Lyketsos CG, Baker L, Warren A, Steele C, Brant J, Steinberg M, Kopunek S, Baker A: Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9:556-561.
9. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:1049-1051.
10. Gonzalez-Salvador T, Aragano C, Lyketsos CG, Barba AC: The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999;14:701-710.
11. Hoch CC, Reynolds CF, Buysse DJ: Two-year survival in patients with mixed symptoms of depression and cognitive impairment: comparison with major depression and primary degenerative dementia. Am J Geriatr Psychiatry 1993;1:59-66.
12. Reifler BV, Teri L, Raskind M, et al: Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45-49.
13. Petracca GM, Chemerimski E, Starkstein SE: A double blind, placebo controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001;3:233-240.
14. Magai C, Kennedy G, Cohen CL, Gomberg D: A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:66-74.
15. Lyketsos CG, Sheppard JM, Steele CD, et al: Randomized, placebo-controlled, doubleblind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry 2000;157:1686-1689.
16. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV: Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction - the DIADS. Arch Gen Psychiatry 2003;60:737-746.
17. Nyth AL, Gottfries CG, Lyby K, et al: A controlled multicenter study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-145.
18. Roth M, Mountjoy CQ, Amrein R: Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168:149-157.
19. Petracca G, Teson A, Chemerinski E, et al: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8:270-275.
20. Amore M, Ricci M, Zanardi R, Perez J, Ferrari G: Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord 1997;46:293-296.
21. Cervera-Enguix S, Baca-Baldomero E, Garcia-Calvo C, Prieto-Lopez R;TESEO Study Group: Depression in primary care: effectiveness of venlafaxine extended-release in elderly patients - observational study. Arch Gerontol Geriatr 2004;3:271-280.
22. Dierick M: An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996;11:169-178.
23. Mahapatra SN, Hackett D: A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209-213.
24. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J: Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004;19:1123-1130.
25. Gasto C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M: Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003;23:21-26.
26. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST: Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16:915-923.
27. Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivastava R: Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995;31:753-758.
28. Owens JR, Nemeroff CB: New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone and mirtazapine. Depress Anxiety 1998;7(suppl 1):24-32.
29. Hansen RA, Gartiehner G, Lohr KN, Gaynes BN, Carey TS: Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-426.
30. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, ed 4, rev. Washington, American Psychiatric Association, 2000.
31. Folstein MF, Folstein SE, McHugh PR: 'Minimental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-198.
32. Alexopoulous GS, Abrams RC, Young RC, et al: Cornell Scale for Depression in Dementia. Biol Psychiatry 1998;23:271-284.
33. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
34. Guy W: ECDEU Assessment Manual for Psychopharmacology (publication 76-338). Washington, US Department of Health, Education and Welfare, 1976.
35. Rockwell E, Lam RW, Zisook S: Antidepressant drug studies in the elderly. Psychiatr Clin North Am 1988;11:26-30.
36. Cunningham LA; Venlafaxine XR 208 Study Group: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997,9:157-164.